Phase I Evaluation of Telatinib, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Combination with Irinotecan and Capecitabine in Patients with Advanced Solid Tumors

M.H.G. Langenberg; P.O. Witteveen; J.M. Roodhart; H.M.W. Verheul; M. Mergui-Roelvink; J. van der Sar; E. Brendel; N. Laferriere; J.H.M. Schellens; E.E. Voest

doi:10.1158/1078-0432.CCR-09-2436

Phase I Evaluation of Telatinib, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Combination with Irinotecan and Capecitabine in Patients with Advanced Solid Tumors

M.H.G. Langenberg, P.O. Witteveen, J.M. Roodhart, H.M.W. Verheul, M. Mergui-Roelvink, J. van der Sar, E. Brendel, N. Laferriere, J.H.M. Schellens, E.E. Voest

Medical oncology

Research output: Contribution to journal › Article › Academic › peer-review

Original language	Undefined/Unknown
Pages (from-to)	2187-2197
Journal	Clinical Cancer Research
Volume	16
Issue number	7
DOIs	https://doi.org/10.1158/1078-0432.CCR-09-2436
Publication status	Published - 2010

Access to Document

10.1158/1078-0432.CCR-09-2436

Cite this

Langenberg, M. H. G., Witteveen, P. O., Roodhart, J. M., Verheul, H. M. W., Mergui-Roelvink, M., van der Sar, J., Brendel, E., Laferriere, N., Schellens, J. H. M., & Voest, E. E. (2010). Phase I Evaluation of Telatinib, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Combination with Irinotecan and Capecitabine in Patients with Advanced Solid Tumors. Clinical Cancer Research, 16(7), 2187-2197. https://doi.org/10.1158/1078-0432.CCR-09-2436

@article{edf207e978e245aba067132cbec8e3a0,

title = "Phase I Evaluation of Telatinib, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Combination with Irinotecan and Capecitabine in Patients with Advanced Solid Tumors",

author = "M.H.G. Langenberg and P.O. Witteveen and J.M. Roodhart and H.M.W. Verheul and M. Mergui-Roelvink and {van der Sar}, J. and E. Brendel and N. Laferriere and J.H.M. Schellens and E.E. Voest",

year = "2010",

doi = "10.1158/1078-0432.CCR-09-2436",

language = "Undefined/Unknown",

volume = "16",

pages = "2187--2197",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "7",

}

Langenberg, MHG, Witteveen, PO, Roodhart, JM, Verheul, HMW, Mergui-Roelvink, M, van der Sar, J, Brendel, E, Laferriere, N, Schellens, JHM & Voest, EE 2010, 'Phase I Evaluation of Telatinib, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Combination with Irinotecan and Capecitabine in Patients with Advanced Solid Tumors', Clinical Cancer Research, vol. 16, no. 7, pp. 2187-2197. https://doi.org/10.1158/1078-0432.CCR-09-2436

Phase I Evaluation of Telatinib, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Combination with Irinotecan and Capecitabine in Patients with Advanced Solid Tumors. / Langenberg, M.H.G.; Witteveen, P.O.; Roodhart, J.M. et al.

In: Clinical Cancer Research, Vol. 16, No. 7, 2010, p. 2187-2197.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Phase I Evaluation of Telatinib, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Combination with Irinotecan and Capecitabine in Patients with Advanced Solid Tumors

AU - Langenberg, M.H.G.

AU - Witteveen, P.O.

AU - Roodhart, J.M.

AU - Verheul, H.M.W.

AU - Mergui-Roelvink, M.

AU - van der Sar, J.

AU - Brendel, E.

AU - Laferriere, N.

AU - Schellens, J.H.M.

AU - Voest, E.E.

PY - 2010

Y1 - 2010

U2 - 10.1158/1078-0432.CCR-09-2436

DO - 10.1158/1078-0432.CCR-09-2436

M3 - Article

C2 - 20233884

VL - 16

SP - 2187

EP - 2197

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 7

ER -

Langenberg MHG, Witteveen PO, Roodhart JM, Verheul HMW, Mergui-Roelvink M, van der Sar J et al. Phase I Evaluation of Telatinib, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Combination with Irinotecan and Capecitabine in Patients with Advanced Solid Tumors. Clinical Cancer Research. 2010;16(7):2187-2197. doi: 10.1158/1078-0432.CCR-09-2436